stoxline Quote Chart Rank Option Currency Glossary
  
UroGen Pharma Ltd. (URGN)
29.655  -0.215 (-0.72%)    11-18 13:51
Open: 29.57
High: 30.16
Volume: 449,130
  
Pre. Close: 29.87
Low: 28.147
Market Cap: 1,455(M)
Technical analysis
2026-11-18 1:18:40 PM
Short term     
Mid term     
Targets 6-month :  38.04 1-year :  44.81
Resists First :  32.57 Second :  38.36
Pivot price 28.77
Supports First :  23.19 Second :  19.29
MAs MA(5) :  27.94 MA(20) :  30.14
MA(100) :  39.54 MA(250) :  29.99
MACD MACD :  -2.6 Signal :  -3
%K %D K(14,3) :  49.8 D(3) :  37.9
RSI RSI(14): 42.5
52-week High :  50.81 Low :  16.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ URGN ] has closed below upper band by 46.8%. Bollinger Bands are 60.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 29.94 - 30.05 30.05 - 30.14
Low: 26.8 - 26.93 26.93 - 27.04
Close: 29.66 - 29.88 29.88 - 30.05
Company Description

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Headline News

Sat, 14 Nov 2026
A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $58 to $75 - Moomoo

Sat, 14 Nov 2026
UroGen Pharma Ltd. (URGN) stock price, news, quote and history - Yahoo Finance UK

Wed, 04 Nov 2026
UroGen Pharma Ltd. (URGN) Q3 FY2026 earnings call transcript - Yahoo Finance

Wed, 04 Nov 2026
UroGen Pharma Ltd (URGN) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits

Wed, 28 Oct 2026
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60 - 富途牛牛

Tue, 13 Oct 2026
UroGen Pharma: An Emerging GARP Stock - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 49 (M)
Shares Float 44 (M)
Held by Insiders 3.4 (%)
Held by Institutions 98.1 (%)
Shares Short 5,610 (K)
Shares Short P.Month 6,250 (K)
Stock Financials
EPS -1.31
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.55
Profit Margin -26.3 %
Operating Margin 9.3 %
Return on Assets (ttm) -8.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 223.8 %
Gross Profit (p.s.) 4.66
Sales Per Share 5.1
EBITDA (p.s.) -0.63
Qtrly Earnings Growth 0 %
Operating Cash Flow -132 (M)
Levered Free Cash Flow -97 (M)
Stock Valuations
PE Ratio -22.3
PEG Ratio 0
Price to Book value -11.46
Price to Sales 5.72
Price to Cash Flow -10.87
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android